HER2 negative, untreated, unresectable advanced or recurrent G/GEJ adenocarcinoma. 72.5% male, 50.8% with age ≥ 65, 54% ECOG 0, 55% from Japan, 41% from South Korea, and 4% from Taiwan. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.